MNMD

MNMD

USD

Mind Medicine (MindMed) Inc. Common Shares

$12.000-0.100 (-0.826%)

Цена в режиме реального времени

Healthcare
Биотехнология
Соединенные Штаты

График цен

Loading Chart...

Ключевые показатели

Рыночные показатели
Фундаментальные показатели компании
Статистические данные торговли

Рыночные показатели

Открытие

$12.100

Максимум

$12.530

Минимум

$11.880

Объем

2.12M

Фундаментальные показатели компании

Рыночная капитализация

1.2B

Отрасль

Биотехнология

Страна

United States

Статистические данные торговли

Средний объем

1.69M

Биржа

NMS

Валюта

USD

52-недельный диапазон

Минимум $4.7Текущая $12.000Максимум $14.43

Связанные новости

BusinessWire

Mind Medicine (MindMed) Inc. Announces Closing of Approximately $259 Million Public Offering, Including Full Exercise of the Underwriters' Option to Purchase Additional Shares

Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the closing

Просмотреть больше
Mind Medicine (MindMed) Inc. Announces Closing of Approximately $259 Million Public Offering, Including Full Exercise of the Underwriters' Option to Purchase Additional Shares
BusinessWire

Mind Medicine (MindMed) Inc. Announces Pricing of $225 Million Public Offering

Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the pricing

Просмотреть больше
Mind Medicine (MindMed) Inc. Announces Pricing of $225 Million Public Offering
BusinessWire

MindMed Announces New Employee Inducement Grant

Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the issuance

Просмотреть больше
MindMed Announces New Employee Inducement Grant
Analyst Upgrades

Mind Medicine Analyst Cites Strong Phase 3 Pipeline For Anxiety, Depression

Needham starts MindMed at Buy with a $28 target, citing strong Phase 3 prospects for MM120 in anxiety and depression and solid cash position.

Просмотреть больше
Mind Medicine Analyst Cites Strong Phase 3 Pipeline For Anxiety, Depression

Оставаться в курсе

Установите ценовой сигнал, получите обновления анализа ИИ и новости рынка в режиме реального времени.